U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.

Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.

RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial

Pancreatic cancer is considered one of the hardest to treat and most serious cancers